NICE technology appraisals on chemotherapy for lung cancer
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing is indicated in adults with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Patients with EGFR‑TK mutation-positive tumours gain more benefit from treatment with EGFR‑TK inhibitors than from standard chemotherapy treatment whereas patients mutation-negative tumours gain more benefit from standard chemotherapy than from EGFR‑TK inhibitors.